Cooper Wendy, Fox Stephen, O'Toole Sandra, Morey Adrienne, Frances Glenn, Pavlakis Nick, O'Byrne Kenneth, Dettrick Andrew, Leong Trishe, Rathi Vivek, Spagnolo Dominic, Hemmings Chris, Singh Mahendra, Moffat David, Tsao Ming-Sound, Wilner Keith, Buller Richard, Pitman Lowenthal Susan, Arifeen Shams, Binko Justin, Alam Mahmood
Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; School of Medicine, University of Western Sydney, Sydney, New South Wales, Australia.
Asia Pac J Clin Oncol. 2014 Apr;10 Suppl 2:11-7. doi: 10.1111/ajco.12190.
The global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Conference, in Sydney on October 31, 2013. It is based on the presentations given by the authors at the meeting and the discussion that ensued. The content for this article was discussed and agreed on by the authors.
随着国际肺癌研究协会（IASLC）/美国病理学家学会（CAP）指南以及《ALK图谱》的近期发布，分子检测的全球格局正在迅速变化。IASLC/CAP指南建议，除了检测表皮生长因子受体（EGFR）突变外，还应对非小细胞肺癌（NSCLC）患者的肿瘤进行ALK重排检测。提出这一建议的原因是有针对这些重排的新型疗法可供使用。本文基于2013年10月31日在悉尼举行的第15届世界肺癌大会前后召开的辉瑞赞助的肺癌ALK诊断全国工作组会议的报道。它基于作者在会议上的发言以及随后的讨论。本文内容经作者讨论并达成一致。
